This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zaarur, N. Articles by Sherman, M. Y. Search for Related Content PubMed PubMed Citation Articles by Zaarur, N. Articles by Sherman, M. Y.

Targeting Heat Shock Response to Sensitize Cancer Cells to Proteasome and Hsp90 Inhibitors

¹ Department of Biochemistry, Boston University School of Medicine; ² Department of Chemistry and Center for Chemical Methodology and Library Development, Boston University; and ³ Department of Radiation Oncology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts

Requests for reprints: Michael Y. Sherman, Department of Biochemistry, Boston University Medical School, 715 Albany Street, Boston, MA 02118. Phone: 617-638-5971; Fax: 617-638-5339; E-mail: sherman{at}biochem.bumc.bu.edu.

Novel classes of anticancer drugs, including proteasome inhibitors and Hsp90 inhibitors, potently induce heat shock proteins (Hsps). Because Hsps show antiapoptotic activities, we suggested that suppression of such induction may sensitize cancer cells to these drugs. Here, we knocked out the major heat shock transcription factor HSF-1 in several cancer cell lines using small interfering RNA and showed that such cells, which can no longer induce Hsps in response to proteasome and Hsp90 inhibitors, become more sensitive to these drugs. Furthermore, we developed a high-throughput screen for small molecules that inhibit induction of Hsps. The first step was a cell-based screen for inhibitors of Hsps-mediated luciferase refolding followed by a counterscreen for toxicity. The second step was a direct testing for inhibition of Hsp induction by immunoblotting with anti-Hsp72 antibody. After screening of 20,000 compounds from several diversity libraries, we focused on a compound we called NZ28, which potently inhibited induction of Hsps by heat shock, proteasome, and Hsp90 inhibitors in a variety of cell lines, and showed no significant toxicity. After testing of a set of analogues of NZ28, we identified a structural element that was critical for the activity. We also identified another inhibitor of the Hsp induction that was practically nontoxic. This compound, which we called emunin, strongly sensitized myeloma cells to proteasome and Hsp90 inhibitors and prostate carcinoma cells to proteasome inhibitors. This work indicates that targeting the heat shock response may facilitate use of proteasome and Hsp90 inhibitors for cancer treatment. (Cancer Res 2006; 66(3): 1783-91)

This article has been cited by other articles:

				N. Zaarur, A. B. Meriin, V. L. Gabai, and M. Y. Sherman Triggering Aggresome Formation: DISSECTING AGGRESOME-TARGETING AND AGGREGATION SIGNALS IN SYNPHILIN 1 J. Biol. Chem., October 10, 2008; 283(41): 27575 - 27584. [Abstract] [Full Text] [PDF]

				W.-Y. Chen, F.-R. Chang, Z.-Y. Huang, J.-H. Chen, Y.-C. Wu, and C.-C. Wu Tubocapsenolide A, a Novel Withanolide, Inhibits Proliferation and Induces Apoptosis in MDA-MB-231 Cells by Thiol Oxidation of Heat Shock Proteins J. Biol. Chem., June 20, 2008; 283(25): 17184 - 17193. [Abstract] [Full Text] [PDF]

				R. Valgardsdottir, I. Chiodi, M. Giordano, A. Rossi, S. Bazzini, C. Ghigna, S. Riva, and G. Biamonti Transcription of Satellite III non-coding RNAs is a general stress response in human cells Nucleic Acids Res., February 2, 2008; 36(2): 423 - 434. [Abstract] [Full Text] [PDF]

				P. M. Voorhees, Q. Chen, D. J. Kuhn, G. W. Small, S. A. Hunsucker, J. S. Strader, R. E. Corringham, M. H. Zaki, J. A. Nemeth, and R. Z. Orlowski Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma Clin. Cancer Res., November 1, 2007; 13(21): 6469 - 6478. [Abstract] [Full Text] [PDF]

				H.-Q. Wang, Z.-X. Du, H.-Y. Zhang, and D.-X. Gao Different Induction of GRP78 and CHOP as a Predictor of Sensitivity to Proteasome Inhibitors in Thyroid Cancer Cells Endocrinology, July 1, 2007; 148(7): 3258 - 3270. [Abstract] [Full Text] [PDF]

				J. Bae, C. Mitsiades, Y.-T. Tai, R. Bertheau, M. Shammas, R. B. Batchu, C. Li, L. Catley, R. Prabhala, K. C. Anderson, et al. Phenotypic and Functional Effects of Heat Shock Protein 90 Inhibition on Dendritic Cell J. Immunol., June 15, 2007; 178(12): 7730 - 7737. [Abstract] [Full Text] [PDF]

				K. Gabrielson, D. Bedja, S. Pin, A. Tsao, L. Gama, B. Yuan, and N. Muratore Heat Shock Protein 90 and ErbB2 in the Cardiac Response to Doxorubicin Injury Cancer Res., February 15, 2007; 67(4): 1436 - 1441. [Abstract] [Full Text] [PDF]

				X. Zhao, H. Shi, A. Sevilimedu, N. Liachko, H. C. M. Nelson, and J. T. Lis An RNA aptamer that interferes with the DNA binding of the HSF transcription activator Nucleic Acids Res., August 7, 2006; 34(13): 3755 - 3761. [Abstract] [Full Text] [PDF]